Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bones Clear all
Completed Phase 2 Interventional

Nutrients and Hormones: Effects in Boys With Disordered Growth

NCT00139451
View directory record Official record
Conditions
Constitutional Growth Delay, Nutrition Disorders, Growth Disorders
Interventions
Pediasure, GH
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 23, 2026, 3:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Muscle Function After Ankle Surgery

NCT00060970
View directory record Official record
Conditions
Muscle Atrophy, Muscle Weakness, Fractures
Interventions
Physical Therapy
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

NCT03397173
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Interventions
Azacitidine, Ascorbic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02019069
View directory record Official record
Conditions
Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
liposomal cytarabine-daunorubicin CPX-351
Drug
Lead sponsor
Rondeep Brar
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 23, 2026, 3:23 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

NCT06325566
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Rexlemestrocel-L + HA mixture, Saline
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 3:23 AM EDT
Not listed Phase 3 Interventional Results available

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 59 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
170
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Southern Bone & Joint Study - Brimless Sockets

NCT01416129
View directory record Official record
Conditions
Socket Designs of Transfemoral Amputees.
Interventions
Standard of care socket, Prosthetic brimless socket
Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 23, 2026, 3:23 AM EDT
Recruiting Early Phase 1 Interventional

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

NCT02356653
View directory record Official record
Conditions
Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes, Immunodeficiencies, Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Interventions
Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 30 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

NCT00685295
View directory record Official record
Conditions
Pain, Fracture, Sprain
Interventions
Fentanyl, Lansoprazole, Oxycodone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Resistance Training on Musculoskeletal Endocrine Interactions

NCT02040727
View directory record Official record
Conditions
Musculoskeletal and Metabolic Crosstalk
Interventions
Resistance Training, No Resistance Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Years to 12 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 23, 2026, 3:23 AM EDT
Terminated Not applicable Interventional

WRx Distal Radius Wrist Fracture Study

NCT01293227
View directory record Official record
Conditions
Wrist Fracture
Interventions
Surgical treatment of distal radius fractures
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption

NCT04102761
View directory record Official record
Conditions
Internal Disc Disruption
Interventions
Intradiscal PRP & BMC Injections
Procedure
Lead sponsor
Annu Navani
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Campbell, California • Los Angeles, California • Tyler, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Jul 23, 2026, 3:23 AM EDT
Completed No phase listed Observational

Low Dose Irradiation for Small Bowel Transplant

NCT00382486
View directory record Official record
Conditions
Irreversible Intestinal Failure, Allograft Rejection
Interventions
Reduce the risk of allograft rejection
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
17 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Jul 23, 2026, 3:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

NCT06090669
View directory record Official record
Conditions
Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies
Interventions
imatinib, TruSight Oncology
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Tabectedin to Treat Children and Adolescents With Cancer

NCT01453283
View directory record Official record
Conditions
Solid Tumors
Interventions
Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537
View directory record Official record
Conditions
Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
Interventions
rigosertib sodium
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

NCT00003239
View directory record Official record
Conditions
Leukemia
Interventions
Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

Vacuum Assisted Closure as a Treatment for Open Fractures

NCT00582361
View directory record Official record
Conditions
Orthopaedic Traumatic Open Fractures
Interventions
Standard Wound Dressing, VAC
Procedure · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

NCT04169373
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

NCT00002766
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
dactinomycin, sargramostim, carmustine, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, mercaptopurine, methotrexate, mitoxantrone hydrochloride, pegaspargase, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 23, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

NCT03009045
View directory record Official record
Conditions
Bone and Joint Infection
Interventions
Tedizolid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

NCT03287245
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Idasanutlin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Kansas City, Kansas • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 23, 2026, 3:23 AM EDT
Completed No phase listed Observational

Re-operation Rates of Concorde Bullet Device Versus Conduit Titanium Interbody Graft for Lumbar Fusion

NCT05993195
View directory record Official record
Conditions
Degenerative Spondylolisthesis, Lumbar Spondylosis, Lumbar Spondylolisthesis
Interventions
Conduit Titanium Interbody Graft, Concorde Bullet Device
Device
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 23, 2026, 3:23 AM EDT